Glen Harbor Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Glen Harbor Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-228	Closed	-$115K	–	1329
2019 Q2	$115K	Sell	228 -72	-24%	-$50.8K	﹤0.01%	1146
2019 Q1	$298K	Sell	300 -301	-50%	-$280K	0.01%	865
2018 Q4	$522K	Sell	601 -287	-32%	-$267K	0.01%	600
2018 Q3	$918K	Buy	888 +60	+7%	+$58.7K	0.02%	501
2018 Q2	$761K	Buy	828 +22	+3%	+$23.6K	0.02%	514
2018 Q1	$786K	Buy	806 +681	+545%	+$621K	0.02%	470
2017 Q4	$57K	Sell	125 -84	-40%	-$31K	﹤0.01%	1220
2017 Q3	$87K	Sell	209 -27	-11%	-$10.2K	﹤0.01%	1146
2017 Q2	$83K	Sell	236 -78	-25%	-$30.1K	﹤0.01%	1125
2017 Q1	$161K	Hold	314	–	–	﹤0.01%	788
2016 Q4	$111K	Buy	+314	New	+$133K	﹤0.01%	872

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Glen Harbor Capital Management's ATRA Position: Q3 2019 in Review

Glen Harbor Capital Management sold out of Atara Biotherapeutics (ATRA) in Q3 2019, closing a stake of 228 shares — an estimated $115K sold.

Glen Harbor Capital Management first reported a position in ATRA in Q4 2016 and held it in 11 quarters. The position peaked at $918K in Q3 2018. 112 funds tracked by Wall St. Rank hold ATRA as of Q3 2019.

Glen Harbor Capital Management reported no remaining Atara Biotherapeutics position as of Q3 2019 after selling out during the quarter.
Glen Harbor Capital Management sold 228 Atara Biotherapeutics shares in Q3 2019, an estimated $115K.
Glen Harbor Capital Management first reported a position in Atara Biotherapeutics in Q4 2016 and held it in 11 quarters.
Glen Harbor Capital Management's Atara Biotherapeutics position peaked at $918K in Q3 2018.
112 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.